Back to List View Graph View

Melanoma

Melanoma is a malignant neoplasm arising from melanocytes, the pigment-producing cells responsible for melanin synthesis.

Where the papers sit

16 papers from the last 6 months study melanoma directly · updated from PubMed 15 Nov 2026

Those 16 are all about one subject.

  • Melanoma Biology and Care

    Clinical care, disease biology, epidemiology, and experimental treatment all converge on improving melanoma outcomes. Recurring topics include delayed recurrence, metastatic prognosis, immunotherapy delivery and volume, immune-cell states, and perioperative rehabilitation. Nanotheranostic and topical approaches pair imaging or targeted delivery with photothermal, photodynamic, chemo- or chemodynamic treatment. The breadth supports a shared focus on melanoma but not a single research trajectory.

    16 papers

NEW DIRECTION

Leptomeningeal melanoma is presented as a neurological cause of catatonia–delirium requiring symptom-directed end-of-life management

The case of advanced leptomeningeal melanoma departs from the set’s predominant roles for melanoma as a tumor target, prognostic condition, epidemiologic burden, or immune-biologic model by treating it as the setting for fluctuating catatonic and delirious signs. The patient’s catatonic signs transiently improved with lorazepam but functional recovery did not follow, while agitation and safety concerns led to discontinuation of lorazepam and introduction of haloperidol. This shifts the practical focus from controlling melanoma or predicting its course to balancing diagnostic uncertainty, sedation, agitation, and comfort during hospice transition 42972997Nov.

Papers

The 16 papers from the last 6 months that study melanoma directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Melanoma Biology and Care (16)
  1. Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care. Palliative & supportive care · 3 Nov 2026 PMID 42972997
  2. Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969691
  3. Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post-Primary Tumor Diagnosis. Cancer medicine · 29 Oct 2026 PMID 42952107
  4. Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
  5. Light- and ROS-responsive nanomicelles enable targeted combination photothermal molecular therapy in melanoma cells and spheroids. Nanoscale · 16 Oct 2026 PMID 42886165
  6. Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
  7. Deciphering the crosstalk between cancer stemness and the immune microenvironment in melanoma: a single-cell transcriptomic analysis. Dermatology (Basel, Switzerland) · 12 Oct 2026 PMID 42862771
  8. The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
  9. Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040. PloS one · 11 Sept 2026 PMID 42727032
  10. Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China. PloS one · 9 Sept 2026 PMID 42715204
  11. A Coordinated Approach to Perioperative Rehabilitation to Enhance Outcomes in Melanoma: Protocol for the CARE-Melanoma Pilot Randomized Controlled Trial. JMIR research protocols · 21 Aug 2026 PMID 42628027
  12. Pluronic F127 engineered nanotheranostics for NIR-II fluorescence imaging and enhanced photodynamic therapy in melanoma. Journal of materials chemistry. B · 30 Jul 2026 PMID 42530322
  13. L-Dopa-asparagine-derived carbon dots as a targeted theranostic agent for melanoma. Chemical communications (Cambridge, England) · 28 Jul 2026 PMID 42517688
  14. QbD-engineered EGCG-rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanoma efficacy. International journal of pharmaceutics · 25 Jul 2026 PMID 42501769
  15. Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells. Cancer immunology research · 11 Jun 2026 PMID 42275481
  16. A pH/glutathione-dual-responsive drug-loaded heterostructure nanozyme for synergistic chemotherapy/chemodynamic therapy against melanoma. Journal of colloid and interface science · 3 Jun 2026 PMID 42235265

By study type

Clinical trials (1)
  1. A Coordinated Approach to Perioperative Rehabilitation to Enhance Outcomes in Melanoma: Protocol for the CARE-Melanoma Pilot Randomized Controlled Trial. JMIR research protocols · 21 Aug 2026 PMID 42628027
Observational studies and case reports (4)
  1. Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care. Palliative & supportive care · 3 Nov 2026 PMID 42972997
  2. Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post-Primary Tumor Diagnosis. Cancer medicine · 29 Oct 2026 PMID 42952107
  3. The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
  4. Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China. PloS one · 9 Sept 2026 PMID 42715204
Human data, design not indexed (2)
  1. Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
  2. Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040. PloS one · 11 Sept 2026 PMID 42727032
Preclinical: animal, cell and lab studies (8)
  1. Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969691
  2. Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
  3. Light- and ROS-responsive nanomicelles enable targeted combination photothermal molecular therapy in melanoma cells and spheroids. Nanoscale · 16 Oct 2026 PMID 42886165
  4. Pluronic F127 engineered nanotheranostics for NIR-II fluorescence imaging and enhanced photodynamic therapy in melanoma. Journal of materials chemistry. B · 30 Jul 2026 PMID 42530322
  5. L-Dopa-asparagine-derived carbon dots as a targeted theranostic agent for melanoma. Chemical communications (Cambridge, England) · 28 Jul 2026 PMID 42517688
  6. QbD-engineered EGCG-rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanoma efficacy. International journal of pharmaceutics · 25 Jul 2026 PMID 42501769
  7. Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells. Cancer immunology research · 11 Jun 2026 PMID 42275481
  8. A pH/glutathione-dual-responsive drug-loaded heterostructure nanozyme for synergistic chemotherapy/chemodynamic therapy against melanoma. Journal of colloid and interface science · 3 Jun 2026 PMID 42235265
Unclassified: not yet indexed with MeSH (1)
  1. Deciphering the crosstalk between cancer stemness and the immune microenvironment in melanoma: a single-cell transcriptomic analysis. Dermatology (Basel, Switzerland) · 12 Oct 2026 PMID 42862771